Literature DB >> 19812381

Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents.

Zhao-Yang Wang1, Ye-Xiong Li, Wei-Hu Wang, Jing Jin, Hua Wang, Yong-Wen Song, Qing-Feng Liu, Shu-Lian Wang, Yue-Ping Liu, Shu-Nan Qi, Hui Fang, Xin-Fan Liu, Zi-Hao Yu.   

Abstract

Extranodal nasal-type natural killer (NK)/T-cell lymphoma is rarely observed in children and adolescents. We aim to investigate the clinical features, prognosis, and treatment outcomes in these patients. Thirty-seven patients were reviewed. There were 19, 14, 2, and 2 patients with stage I, stage II, stage III, and stage IV diseases, respectively. Among the patients with stage I and II disease, 19 patients received initial radiotherapy with or without chemotherapy, and 14 patients received chemotherapy followed by radiotherapy. The 4 patients with stage III and IV disease received primary chemotherapy and radiation of the primary tumor. Children and adolescents with extranodal nasal-type NK/T-cell lymphoma usually presented with early-stage disease, high frequency of B symptoms, good performance, low-risk age-adjusted international prognostic index, and chemoresistance. The complete response rate after initial radiotherapy was 73.7%, which was significantly higher than the response rate after initial chemotherapy (16.7%; P = .002). The 5-year overall survival (OS) and progression-free survival (PFS) rates for all the patients were 77.0% and 68.5%, respectively. The corresponding OS and PFS rates for patients with stage I and II disease were 77.6% and 72.3%, respectively. Children and adolescents with early-stage extranodal nasal-type NK/T-cell lymphoma treated with primary radiotherapy had a favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812381     DOI: 10.1182/blood-2009-07-235853

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  NK/T Cell Lymphoma: A Tertiary Centre Experience.

Authors:  Neeraj Arora; Arpan Mehta; Sriram Ravichandran; Indu Arun; Rimpa Basu Achari; Anupam Chakrapani; Saurabh Jayant Bhave; Mammen Chandy; Reena Nair
Journal:  Indian J Hematol Blood Transfus       Date:  2016-04-21       Impact factor: 0.900

2.  Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study.

Authors:  Y Yang; Y-J Zhang; Y Zhu; J-Z Cao; Z-Y Yuan; L-M Xu; J-X Wu; W Wang; T Wu; B Lu; S-Y Zhu; L-T Qian; F-Q Zhang; X-R Hou; Q-F Liu; Y-X Li
Journal:  Leukemia       Date:  2015-02-20       Impact factor: 11.528

3.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

4.  Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.

Authors:  Paola Ghione; Shunan Qi; Brandon S Imber; Venkatraman Seshan; Alison Moskowitz; Natasha Galasso; Matthew Lunning; David Straus; Craig Sauter; Parastoo Dahi; Ahmet Dogan; Joachim Yahalom; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2020-08-26

5.  Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma: results of a clinical trial.

Authors:  Agustin Avilés; Natividad Neri; Raúl Fernández; Judith Huerta-Guzmán; Maria-Jesus Nambo
Journal:  Med Oncol       Date:  2013-06-25       Impact factor: 3.064

6.  Prophylactic cervical lymph node irradiation provides no benefit for patients of stage IE extranodal natural killer/T cell lymphoma, nasal type.

Authors:  Liang Wang; Zhong-Jun Xia; Yue Lu; Yu-Jing Zhang
Journal:  Med Oncol       Date:  2014-11-28       Impact factor: 3.064

7.  [Cutaneous malignant lymphomas. Update on diagnosis and therapy of cutaneous T-cell lymphomas].

Authors:  D Humme; M Möbs; S Pullmann; A Haidar; M Beyer; W Sterry; C Assaf
Journal:  Hautarzt       Date:  2012-05       Impact factor: 0.751

8.  Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.

Authors:  Shunan Qi; Joachim Yahalom; Meier Hsu; Monica Chelius; Matthew Lunning; Alison Moskowitz; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2016-05-17

Review 9.  NK/T-cell lymphomas in children.

Authors:  Catherine Lai; Kieron Dunleavy
Journal:  Best Pract Res Clin Haematol       Date:  2013-05-23       Impact factor: 3.020

10.  Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group.

Authors:  Tao Wu; Yong Yang; Su-Yu Zhu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Chen Hu; Shu-Nan Qi; Bo Chen; Ye-Xiong Li
Journal:  Blood Adv       Date:  2018-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.